{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:13:11Z","timestamp":1780107191775,"version":"3.54.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1136\/ijgc-2020-002225","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T05:50:11Z","timestamp":1630907411000},"page":"1292-1296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-term response to olaparib in BRCA1-related ovarian cancer with brain metastases"],"prefix":"10.1016","volume":"31","author":[{"given":"Alejandro","family":"Gallego","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Y\u00e9benes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mendiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Castelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2020-002225_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-014-1447-9","article-title":"Brain metastasis from ovarian cancer: a systematic review","volume":"119","author":"Pakneshan","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1136\/ijgc-2020-002225_bb0015","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ygyno.2019.03.004","article-title":"Increased risk of brain metastases in ovarian cancer patients with BRCA mutations","volume":"153","author":"Ratner","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002225_bb0020","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.ijrobp.2016.06.153","article-title":"BRCA1 mutations associated with increased risk of brain metastases in breast cancer: a 2:1 matched-pair analysis","volume":"96","author":"Zavitsanos","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2020-002225_bb0025","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/annonc\/mdy216","article-title":"Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors","volume":"29","author":"Diossy","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2020-002225_bb0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10987-3","article-title":"Genomic signatures reveal DNA damage response deficiency in colorectal cancer brain metastases","volume":"10","author":"Sun","year":"2019","journal-title":"Nat Commun"},{"key":"10.1136\/ijgc-2020-002225_bb0035","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2020-002225_bb0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.6002","article-title":"Final overall survival (OS) results from SOLO2\/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (PTS) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation","volume":"38","author":"Poveda","year":"2020","journal-title":"JCO"},{"key":"10.1136\/ijgc-2020-002225_bb0045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.5533","article-title":"Clinically significant long-term maintenance treatment with olaparib in patients (PTS) with platinum-sensitive relapsed serous ovarian cancer (PSR soc)","volume":"35","author":"Gourley","year":"2017","journal-title":"JCO"},{"key":"10.1136\/ijgc-2020-002225_bb0050","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-06-2854","article-title":"The blood-brain barrier and cancer: transporters, treatment, and Trojan horses","volume":"13","author":"Deeken","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2020-002225_bb0055","doi-asserted-by":"crossref","DOI":"10.1186\/1748-717X-7-77","article-title":"Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment","volume":"7","author":"Tallet","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1136\/ijgc-2020-002225_bb0060","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jtho.2018.12.002","article-title":"Efficacy of alectinib in patients with ALK-positive NSCLC and symptomatic or large CNS metastases","volume":"14","author":"Lin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1136\/ijgc-2020-002225_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/1748-717X-8-65","article-title":"Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma","volume":"8","author":"Barazzuol","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1136\/ijgc-2020-002225_bb0070","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.2011","article-title":"A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (PTS) with unmethylated MGMT (uMGMT) glioblastoma (GBM)","volume":"37","author":"Khasraw","year":"2019","journal-title":"JCO"},{"key":"10.1136\/ijgc-2020-002225_bb0075","author":"Mikule","year":"2015","journal-title":"Abstract B168: the PARP inhibitor, niraparib, crosses the blood brain barrier in rodents and is efficacious in a BRCA2-mutant intracranial tumor model"},{"key":"10.1136\/ijgc-2020-002225_bb0080","article-title":"Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases","volume":"36","author":"Nadine","year":"2018","journal-title":"JCO"},{"key":"10.1136\/ijgc-2020-002225_bb0085","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.gore.2016.10.004","article-title":"Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease","volume":"18","author":"Bangham","year":"2016","journal-title":"Gynecol Oncol Rep"},{"key":"10.1136\/ijgc-2020-002225_bb0090","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2020-002225_bb0095","article-title":"Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers","volume":"109","author":"Kotsopoulos","year":"2016","journal-title":"J Natl Cancer Inst"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24004754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24004754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2020-002225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:27:05Z","timestamp":1753234025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24004754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1048891X24004754"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2020-002225","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term response to olaparib in BRCA1-related ovarian cancer with brain metastases","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2020-002225","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}